Cybin Inc.

NYSE American CYBN

Cybin Inc. Shareholders' Equity for the year ending March 31, 2024

Cybin Inc. Shareholders' Equity is NA for the year ending March 31, 2024. Shareholders' equity are the residual interest in the assets of a company after deducting liabilities, representing the shareholders' ownership claim.

Cybin Inc. Shareholders' Equity for the year ending March 31, 2021 was USD 1.15 M.

Key data

Date	Shareholders' Equity	Minority Interest	Total Equity	Total Stockholders Equity and Liabilities

NYSE American: CYBN

Cybin Inc.

CEO	Mr. Douglas L. Drysdale
IPO Date	Sept. 13, 2019
Location	Canada
Headquarters	100 King Street West
Employees	50
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to treat neuroinflammation. It has also developed EMBARK, a psychedelic-assisted psychotherapy. The company is headquartered in Toronto, Canada.

Key trends

Past 5 years